Trials / Completed
CompletedNCT00714961
Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction
A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Clopidogrel Plus Acetylsalicylic Acid (ASA) Versus ASA Alone in Subjects With Acute ST Elevation Myocardial Infarction (STEMI) Treated With Fibrinolytic Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,491 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the combination of aspirin plus clopidogrel is more effective than aspirin alone in preventing another heart attack, chest pain, stroke or death in people who have already had a heart attack that was treated with fibrinolytic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clopidogrel (SR25990) | plus acetylsalicylic acid (ASA) |
| DRUG | Placebo | plus acetylsalicylic acid (ASA) |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2005-01-01
- Completion
- 2005-01-01
- First posted
- 2008-07-14
- Last updated
- 2009-03-25
Locations
24 sites across 24 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Russia, South Africa, Spain, Sweden, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00714961. Inclusion in this directory is not an endorsement.